Top Tweets for #SUROVAStudy

9 months ago

@IJGConline @lchiv4 @ClinicaNavarra But #SUROVAstudy is strongly hypothesis-generating: the longest survivors were those with PDS + R0 + NO postop complications! The key is not PDS vs IDS in theory, but doing the right surgery safely in the right patient!

0

3

0

85

9 months ago

Yesterday we discussed the #SUROVAstudy in the #JournalClub of @IJGConline. In a large PSM cohort, there were no major survival differences between PDS and IDS in advanced ovarian cancer. #gynoncology #ovariancancer @lchiv4 @ClinicaNavarra

Quique_ChC's tweet photo. Yesterday we discussed the #SUROVAstudy in the #JournalClub of @IJGConline. In a large PSM cohort, there were no major survival differences between PDS and IDS in advanced ovarian cancer. #gynoncology #ovariancancer @lchiv4 @ClinicaNavarra https://t.co/SycLt5Dvmv

3

5

4

0

524

9 months ago

✨ Don’t miss our next #IJGCclub! 🗓️ Dec 16 | 11:00 CDT / 18:00 CEST 📖 #SUROVAStudy: Global real-world treatment strategies and mortality risk prediction in advanced #ovariancancer with Luis Chiva @lchiv4 🔗 Don’t miss this engaging discussion: https://t.co/U879Rhb83X @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul

IJGConline's tweet photo. ✨ Don’t miss our next #IJGCclub!
🗓️ Dec 16 | 11:00 CDT / 18:00 CEST
📖 #SUROVAStudy: Global real-world treatment strategies and mortality risk prediction in advanced #ovariancancer with Luis Chiva @lchiv4

🔗 Don’t miss this engaging discussion: https://t.co/U879Rhb83X

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul

0

14

8

0

1K

Ester Miralpeix @ester_miralpeix

9 months ago

#LeadArticle #SUROVAstudy: global real-world treatment strategies and mortality risk prediction in advanced #ovariancancer New global real-world data (n=3,286) finds no difference in 5-year survival between primary surgery & neoadjuvant chemo for advanced ovarian cancer. 💡 https://t.co/8qKnuuFAzY @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul @lchiv4

IJGConline's tweet photo. #LeadArticle #SUROVAstudy: global real-world treatment strategies and mortality risk prediction in advanced #ovariancancer

New global real-world data (n=3,286) finds no difference in 5-year survival between primary surgery & neoadjuvant chemo for advanced ovarian cancer.

💡 https://t.co/8qKnuuFAzY

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul @lchiv4

2

22

11

6

2K

9 months ago

Don’t miss the #SUROVAstudy #IJGCconversations Great debate on patient selection for primary or interval debulking surgery in #ovariancancer to achieve complete resection without complications. Grateful to hear that #prehabilitation and #ERAS could be considered! @pedroramirezMD

9 months ago

The big debate in #ovariancancer continues🔥 🔥 🎙️ Tune into our new #IJGCconversations episode with Dr. Luis Chiva @lchiv4 discussing the #SUROVAstudy 🎧 https://t.co/2HEenVBncf @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul

3

21

11

7

2K

1

6

2

0

442

9 months ago

The big debate in #ovariancancer continues🔥 🔥 🎙️ Tune into our new #IJGCconversations episode with Dr. Luis Chiva @lchiv4 discussing the #SUROVAstudy 🎧 https://t.co/2HEenVBncf @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul

3

21

11

7

2K

over 1 year ago

Many thanks also to Prof. Dennis Chi for the discussion, his advice will certainly improve the final paper! #SUROVAStudy #Esgo2025 @MSKCancerCenter @lchiv4 @ClinicaNavarra @ESGO_society

Quique_ChC's tweet photo. Many thanks also to Prof. Dennis Chi for the discussion, his advice will certainly improve the final paper!

#SUROVAStudy #Esgo2025

@MSKCancerCenter @lchiv4 @ClinicaNavarra @ESGO_society https://t.co/2BhK9l3gIF

0

11

3

0

651